Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for Older Patients With AML
NCT00623935Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2007
- Primary completion
- Jun 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan in acute myeloid leukemia (AML), sponsored by University of Michigan Rogel Cancer Center. Started Mar 2007; status: completed.
02
Drugs
fludarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00623935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623935.